Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
2(40%)
Results Posted
67%(2 trials)

Phase Distribution

Ph phase_2
2
40%
Ph phase_1
1
20%
Ph not_applicable
2
40%

Phase Distribution

1

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
2(40.0%)
N/ANon-phased studies
2(40.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

5

all time

Status Distribution
Active(2)
Completed(3)

Detailed Status

Completed3
Active, not recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
2
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (20.0%)
Phase 22 (40.0%)
N/A2 (40.0%)

Trials by Status

completed360%
active_not_recruiting120%
recruiting120%

Recent Activity

2 active trials
Showing 5 of 5
completedphase_1

Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL

NCT04155710
completednot_applicable

Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic Melanoma

NCT01005745
completednot_applicable

Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts

NCT01701674
active_not_recruitingphase_2

Study of High Dose Interleukin-2 (IL-2) and Stereotactic Body Radiation (SBRT) in Patients With Metastatic Renal Cancer

NCT02306954
recruitingphase_2

Evaluation of a Pragmatic Approach to Adoptive Cell Therapy (ACT) Using an IL2 Analog (ANV419) vs High Dose IL2 After Tumor Infiltrating Lymphocytes (TIL) Therapy in Patients With Melanoma, NSCLC and Cervical Cancer (PragmaTIL)

NCT06630611

Clinical Trials (5)

Showing 5 of 5 trials
NCT04155710Phase 1

Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL

Completed
NCT01005745Not Applicable

Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic Melanoma

Completed
NCT01701674Not Applicable

Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts

Completed
NCT02306954Phase 2

Study of High Dose Interleukin-2 (IL-2) and Stereotactic Body Radiation (SBRT) in Patients With Metastatic Renal Cancer

Active Not Recruiting
NCT06630611Phase 2

Evaluation of a Pragmatic Approach to Adoptive Cell Therapy (ACT) Using an IL2 Analog (ANV419) vs High Dose IL2 After Tumor Infiltrating Lymphocytes (TIL) Therapy in Patients With Melanoma, NSCLC and Cervical Cancer (PragmaTIL)

Recruiting

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5